Xience v stent. 0 x 48 mm for all stents tested.

Xience v stent 25 mm diameter XIENCE V Stent System (XIENCE nano Stent System) is In all cases, the Xience stent was deployed using a biaxial system composed of a guide catheter and a coronary guidewire. The XIENCE Family of Everolimus Eluting Coronary Stent Systems are indicated for improving coronary luminal diameter in patients with symptomatic heart disease due to de novo native coronary artery lesions for XIENCE V (length ≤ 28 mm), XIENCE PRIME, XIENCE Xpedition and XIENCE Alpine (lengths ≤ 32 Expert opinion: XIENCE® Sierra everolimus-eluting coronary stent carries all the positive features of the precursor stents of the XIENCE® family and brings an ultra-low crossing profile which further increases deliverability and flexibility. Stone G, MD, et al. Bench test data on file at Boston Scientific. Further randomized trials, including ‘all-comer’ patients and The Xience V stent holds the promise of superior anti-restenotic efficacy as well as long-term safety. abbottvascular. 4. 2009;54:269–276. Factors such as surface chemistry, surface roughness, polymer purity, the presence of leachables and other impurities, in vivo stabilityofthepolymer,andtheinteractionwithblood- XIENCE™ Stent Evidence. (A) Normal view, (B) magnified view, and (C) cross-sectional view. A comprehensive preclinical program was completed to aid in the scientific design and to demonstrate the 5-year results of a randomized comparison of XIENCE V everolimus-eluting and TAXUS paclitaxel-eluting stents: final results from the SPIRIT III trial (clinical evaluation of the XIENCE V everolimus eluting coronary stent system in the treatment of patients with de novo native coronary artery lesions) JACC Cardiovasc Interv. ) law to investigational use only. jacc. However, concerns have been raised over late thrombotic events. com. 2. , an Abbott Vascular Company, CA, USA) may provide enhanced deliverability, radiopacity with thinner strut filaments and, owing to a durable polymer, sustained drug elution and vascular compatibility. Abbott’s market-leading XIENCE family Xience V® stent were less evident in patients with diabetes, who represented 18% of the study population, for reasons that are as yet unclear. Pivotal clinical trials have demonstrated the safety and efficacy of both stents. In addition, this stent is based on the Multi-link platform and delivery system. The XIENCE V was approved under P070015; and the XIENCE nano Stent System is a line extension to the XIENCE V Stent System, which was approved under P070015/S054. Recently available data already suggest the superiority of the Xience V stent in comparison to the Taxus stent in terms of prevention of restenosis, without XIENCE Sierra™ Stent Even When Patients Are Complex— Choosing a Stent Shouldn't Be. Everolimus‐eluting stents in patients undergoing percutaneous coronary intervention: final 3‐year results of the clinical evaluation of the XIENCE V Everolimus eluting coronary stent system in the treatment of subjects with de novo native coronary artery lesions trial. Recently available data already suggest the superiority of the Xience V stent in comparison to the Taxus stent in terms of prevention of restenosis, without XIENCE™ Stent Fluoropolymer vs Other Types of Stents. S. XIENCE drug-eluting stents (DES), the world's leading DES, has the lowest rates of late stent thrombosis and unparalleled performance, even in complex patients. 3: Conditional 5 More Coils, Filters, Stents, and Grafts More XIENCE Xpedition Stent The Xience V stent holds the promise of superior anti-restenotic efficacy as well as long-term safety. 2013 Dec;6 Abbott Now Offers a 2. The design of XIENCE Sierra™ Stent is unlike that of other drug-eluting stents (DES). Additionally, the XIENCE V stent is indicated for treating The XIENCE V USA study is designed to evaluate at least 5,000 coronary artery disease patients treated with the XIENCE V drug eluting stent at approximately 250 centers across the United States. Introduction. JACC Cardiovasc Interv . The XIENCE Family of Coronary Stents includes the following: Everolimus Eluting Coronary Stent Systems – XIENCE VTM, XIENCE PRIMETM (including XIENCE PRIME SV, XIENCE PRIME XIENCE Stent differs from other DES in both its unique stent design and fluoropolymer coating. Colombo A, et al. 0 mm diameter and length up to 12 mm. Applies to XIENCE Skypoint™ Stent Systems: Indicated for improving coronary artery luminal diameter in patients, including those with diabetes mellitus, with symptomatic heart disease due to de novo native Background—The Absorb everolimus-eluting bioresorbable vascular scaffold (Absorb) has shown promising clinical results; however, only limited preclinical data have Promus Element platinum chromium everolimus-eluting stent. In the single-arm registry, 400 XIENCE Skypoint, the latest in a line of trusted XIENCE stents, is now approved for use in HBR patients with one-month DAPT labeling – as short as 28 days – in the U. Photos on file at XIENCE V Everolimus Eluting Coronary Stent System Healthcare Professionals. J Am Coll Cardiol. The antiproliferative drug used is everolimus, a hydroxyethyl derivative of sirolimus which acts as an immunosuppressant. Limited by Federal (U. Abbott's XIENCE V is truly a next-generation DES, combining Data presented at the EuroPCR 2012 congress this week demonstrated that in more than 10,000 real-world patients treated with XIENCE PRIME and XIENCE V, no cases of stent thrombosis were reported in patients who discontinued DAPT after three months post-stent implantation. 1016/j. ” The XIENCE Family of Coronary Stents is designed to prevent re-narrowing within the stent (in-stent restenosis). XIENCE™ V The The everolimus-eluting Xience V™ stent has been extensively evaluated in the SPIRIT clinical trial program. Among CAD patients, those Xience V Stent uses the Vision™ platform and has similar results to that of the Multi-Link 8 platform. 50 mm stents; Promus PREMIER Stent n European trial and randomized 60 patients to XIENCE® V stent, or the MULTI-LINK® VISION® bare-metal stent, with target vessels 3. Xience V. 6 Here are a The XIENCE V drug coated stent is used to treat coronary artery disease by propping open a narrowed or blocked artery and releasing the drug, everolimus, in a controlled manner to prevent the The XIENCE V Everolimus Eluting Coronary Stent System (XIENCE V stent) is indicated for improving coronary luminal diameter in patients with symptomatic heart disease due to de novo native coronary artery lesions (length ≤ 28 mm) with reference vessel diameters of 2. This coating is a key differentiator and results in greater thromboresistance and minimal inflammatory response, and promotes faster The XIENCE™ Stent difference results not just from a unique stent design but from a unique fluoropolymer coating. of everolimus with a maximum nominal drug content of 232 μg on the large stent (4. 1−3As a drug/device combination product, the overall performance of a DES is determined by its components and how well they are The XIENCE V Everolimus Eluting Coronary Stent System (XIENCE V stent) is indicated for improving coronary luminal diameter in patients with symptomatic heart disease due to de novo native coronary artery lesions (length d 28 mm) with reference vessel diameters of The same stent (Xience V or Multi-Link Vision) was used for the treatment of multiple lesions in the same vessel (if possible, a single long DES was used, whereas a spot stenting strategy was preferred with BMS). However, limited data are available comparing the XIENCE The XIENCE V and XIENCE nano Everolimus Eluting Coronary Stent System is indicated for improving coronary luminal diameter in patients, including those with diabetes This study sought to investigate the efficacy and performance of the XIENCE V everolimus-eluting stent (EES) (Abbott Vascular, Santa Clara, California) in the treatment of de novo coronary The everolimus-eluting Xience V stent is among the most promising of second generation drug-coated stents designed for the percutaneous treatment of coronary artery We aim at examining the long‐term clinical outcome after Xience everolimus‐eluting stent (X‐EES) implantation. Promus Element uses the same drug and polymer as Xience V/Promus, but has been modified to provide improved deliverability, conformability, radiopacity, radial strength, and fracture resistance. In patients at high bleeding risk undergoing non-complex percutaneous coronary intervention with these stents, a shortened dual antiplatelet therapy (DAPT) regimen of 1–3 months appears to be associated with a reduced rate of major Results: SEM image of an expanded XIENCE™ V stent after the stent has undergone accelerated aging for 2 years was taken. SEM images of the XIENCE V DES (scale = 150×in the left and 80×in the right). This coating is a key differentiator from other DES, resulting in thromboresistance, and minimal inflammatory Data from randomized clinical trials have shown the safety and efficacy of the XIENCE V in selected populations. Background: The XIENCE V™ everolimus-eluting coronary stent system is a second-generation drug-eluting stent designed for safety and efficacy in the interventional treatment of coronary artery disease and in preventing The XIENCE stent systems are indicated for use in patients who have a narrowing in their coronary arteries and are at high risk for bleeding due to previous conditions including, but not limited A new era of prospective real-world safety evaluation primary report of XIENCE V USA (XIENCE V Everolimus Eluting Coronary Stent System condition-of-approval post-market study). 2011; 4 XIENCE V, XIENCE PRIME, and XIENCE Xpedition stent Drug Component; A conformal coating of a non-erodible polymer loaded with 100 μg/cm. 8% and saphenous vein graft intervention of 4. Recently available data already suggest the superiority of the Xience V stent in comparison to the Taxus stent in terms of prevention of restenosis, without The preclinical data, along with the SPIRIT clinical trial data, demonstrate the excellent safety and potential efficacy profile of XIENCE V. . Long‐term clinical outcomes beyond 5 years after X‐EES implantation Objectives: This study sought to evaluate the long-term safety and efficacy of everolimus-eluting stents (EES) and paclitaxel-eluting stents (PES) in patients with obstructive coronary artery The XIENCE V®, XIENCE nano®, XIENCE PRIME®, XIENCE PRIME® LL, XIENCE Xpedition®, XIENCE Xpedition® SV and XIENCE Xpedition® LL, XIENCE Alpine®, and XIENCE SierraTM (XIENCE Family) of The XIENCE family of everolimus-eluting stents is characterized by its cobalt-chromium alloy stent platform with thin struts (81 μm) and a biocompatible fluoropolymer, features and delivery system of the XIENCE V and XIENCE nano are identical to the MULTI-LINK VISON and MULTI-LINK MINI VISION, respectively. 0 mm and lengths of 8, 12, 15, 18, 23, 28 mm. In coronary PCI, the ASAHI Prowater was described as highly maneuverable wire with low friction, The XIENCE V Everolimus Eluting Coronary Stent System (XIENCE V stent) is indicated for improving coronary luminal diameter in patients with symptomatic heart disease due to de novo native coronary artery lesions (length d 28 mm) with reference vessel diameters of Abstract. Applies to XIENCE Skypoint™ Stent Systems: Indicated for improving coronary artery luminal diameter in patients, including those with diabetes mellitus, with symptomatic heart disease due to de novo native The XIENCE V everolimus-eluting stent (EES) (Abbott Vascular, Santa Clara, California) is a second-generation DES designed on the Multilink Vision L-605 cobalt-chromium alloy balloon expandable stent with a 0. It induces cell cycle arrest in the G 1 phase by inhibiting the mammalian target of rapamycin, a serine/threonine protein kinase that regulates cell growth, proliferation, motility, protein synthesis, and transcription, among others. The current trial sought to study the safety and efficacy of one of the so-called “second-generation” stents, Xience V (everolimus-eluting stent [EES]) versus BMS in patients presenting the xience v everolimus eluting coronary stent system (xience v stent) is indicated for improving coronary luminal diameter in patients, including those with diabetes mellitus, with symptomatic heart disease due to de novo native coronary artery lesions (length = 28 mm) with reference vessel diameters of 2. This is the shortest duration of XIENCE V Stent Abbott Vascular www. , May 24, 2011 /PRNewswire/ -- A new era of prospective real-world safety evaluation primary report of XIENCE V USA (XIENCE V Everolimus Eluting Coronary Stent System condition-of-approval post-market study). XIENCE™ Stent’s fluoropolymer demonstrates the fewest platelets adhering to the stent surface—an important factor in XIENCE V™ everolimus-eluting coronary stent is a second-generation DES designed to be more deliverable and safe, while maintaining efficacy in a broad patient population compared with first-generation DES. 8-12 The positive clinical results may reflect superior drug characteristics, polymer morphology, 13,14 and biocompatibility, 15-17 which may account for a better endothelialisation compared with older-generation DES. The XIENCE V failed to demonstrate superiority for overall It is the last iteration of the Xience™ line-up (Xience V™, Xience Prime™, Xience Xpedition™, Xience Alpine™, Xience Sierra™). 05. First‐generation DES have demonstrated high levels of efficacy. Park KW, Chae IH, Lim DS, et al. 5, 4. The XIENCE family of everolimus-eluting stents ranks among the most used and most widely studied drug-eluting stents worldwide. Rationale of the study. Coronary artery disease occurs when plaque build-up narrows the arteries and reduces blood The efficacy of the stent has been demonstrated with low rates of angiographic restenosis, whilst randomized trials comparing the Xience V everolimus-eluting stent to the first-generation Taxus ® paclitaxel-eluting stent have found a reduction in repeat revascularization rates. 014 ASAHI Prowater guidewire (Asahi Intecc, Tokyo, Japan) was exclusively used in each case. The primary endpoint of XIENCE V USA is a measure of stent thrombosis (formation of blood clots) every year out to five years, as defined by the Dublin The efficacy of the stent has been demonstrated with low rates of angiographic restenosis, whilst randomized trials comparing the Xience V everolimus-eluting stent to the first-generation Taxus® paclitaxel-eluted stent have found a reduction in repeat revascularization rates. For The anatomic distribution of the treated vessels was generally comparable among the 3 groups, with overall rates of left main intervention of 1. With its unique design, XIENCE Sierra™ Stent is XIENCE Prime™ BTK Everolimus Eluting Peripheral Stent System is clinically proven for primary stenting of focal and long lesions. 20 Nevertheless, there was no difference in clinical outcome between patients Expert opinion: XIENCE® Sierra everolimus-eluting coronary stent carries all the positive features of the precursor stents of the XIENCE® family and brings an ultra-low crossing profile which further increases However, the 1-year outcomes in the COMPARE trial (NCT01016041), in which 1800 unselected patients were randomly assigned to the XIENCE V everolimus-eluting stent The Cobalt Chromium Everolimus-Eluting Stent (CoCr-EES) Post Marketing Surveillance (PMS) Japan study is a prospective multicenter registry designed to evaluate the safety and efficacy of XIENCE V Xience V. The coating is conformal with no changes after aging. doi: 10. 2 In fact, XIENCE™ Stent consistently has the lowest rate of late and very late stent Indications. The PROMUS (XIENCE V) stent was not evaluated at 360 days because the purpose of the long-term evaluation was to compare the vascular response to the Synergy biodegradable polymer The XIENCE V USA (XIENCE V Everolimus Eluting Coronary Stent System Condition-of-Approval Post-Market Study) sought to evaluate the safety of everolimus-eluting coronary stent systems in a real-world population with a total of 5,054 participants (1,875 standard-risk; 3,179 extended-risk). Methods and results: In the SORT OUT IV (Randomized Clinical Comparison of the Xience V and the Cypher Coronary Stents in Non-Selected Patients With Coronary Heart Disease) trial, the EES demonstrated a significant lower rate of very late ST compared The design of the Evaluation of XIENCE versus Coronary Artery Bypass Surgery for Effectiveness of Left Main Revascularization (EXCEL) trial has been reported previously. The XIENCE™ Stent is effective in a wide range of patients—from simple lesions to complex lesions, and from lower risk individuals to higher risk patients like those with diabetes. SKIP TO CONTENT. 25 mm diameter XIENCE V EECSS is only available on the RX platform. 8,9 The forward in this document, the XIENCE Skypoint, XIENCE PROS, and XIENCE PRO 48 systems will be referred to as the “XIENCE Family of Coronary Stents” or as “XIENCE Stents. Endeavor Resolute and Xience V are two new-generation DES. 2009. XIENCE™ Stent’s fluoropolymer demonstrates the fewest platelets adhering to the stent surface—an important factor in The Xience V stent holds the promise of superior anti-restenotic efficacy as well as long-term safety. 25, 2. A Prospective, Randomized Evaluation of a Novel Everolimus *The 2. 0032 However, these were all conducted with so-called “first-generation” stents, such as sirolimus-eluting stents (SES) and paclitaxel-eluting stents (PES). 1% of patients in the Xience group (difference, 1. The 2. A. Dr smits’ group now plan to conduct The most widely used second-generation DESs, the Xience V/Promus everolimus-eluting stent (EES) (Abbott Vascular, Temecula, California) and the Endeavor Resolute zotarolimus-eluting stent (ZES-R) (Medtronic Cardiovascular, Santa Rosa, California), both made of cobalt-chromium with biocompatible polymers, were compared in only 2 randomized Drug‐eluting stents (DES) are a preferred treatment modality for occlusive coronary artery disease. At the time of this study, it was available in diameters of 2. At 1 year, the rate of Academic Research Consortium Aims: This study evaluated vascular compatibility of the novel platinum chromium alloy Element stent platform delivering abluminal everolimus from a poly-lactide-co-glycolide bioabsorbable polymer (SYNERGY stent), currently undergoing clinical trial, compared with the PROMUS (XIENCE V) and bare metal and polymer-only Element stents. This article summarizes the various studies of this program and their impact on In conclusion, in a contemporary United States clinical practice with an unselected patient population, use of the XIENCE V stent was associated with an improved safety profile and reduction of all-cause mortality and stent thrombosis compared to first-generation drug-eluting stents. The drug distribution imaging and interference patterns for coating thickness uniformity evaluation were taken using focal planar imaging FTIR. Additionally, the XIENCE V stent is indicated for treating The XIENCE V drug coated stent is used to treat coronary artery disease by propping open a narrowed or blocked artery and releasing the drug, everolimus, in a controlled manner to prevent the artery from becoming blocked again following a stent procedure. XIENCE Prime™ BTK The everolimus-eluting stent in real-world patients: 6-month follow-up of the X-SEARCH (Xience V stent evaluated at Rotterdam Cardiac Hospital) registry. 28), which may be related to the more open cell design of the Resolute stent. The XIENCE VTM STENT DESIGN AND RATIONALE Figure 4. Push efficiency comparison is between XIENCE Skypoint™ Stent, XIENCE Xpedition™ Stent, and Synergy ‡ – 3. Everolimus-eluting versus sirolimus- eluting stents in patients XIENCE™ Stent Fluoropolymer vs Other Types of Stents. [Google Scholar] 60. 0 x 48 mm for all stents tested. It was first evaluated in the SPIRIT II trial, a single-blind randomized trial evaluating the Xience V™ everolimus-eluting stent (EES) against the Taxus™ PES in 300 patients. 0, 3. Nevertheless, there are concerns about device deliverability and safety with the initial generation of drug-eluting stents. XIENCE™ Stent is the DES that delivers consistently outstanding short- and long-term patient outcomes. and in Europe. About XIENCE PRIME and XIENCE V. 2011; 4 PLATINUM Clinical Trial Program studied the PROMUS Element™ Stent (Promus PtCr EES) and the Xience V™ Stent (Xience CoCr EES). 016. Drug-eluting stents are widely used for the treatment of coronary artery disease to reduce the risk of restenosis found with bare-metal stents. Supported by 10 years of clinical Indications. XIENCE V – a DES with superior* outcomes that can take your performance to new heights. A comprehensive preclinical program was completed to aid in the scientific design and to demonstrate the PARIS, May 15, 2012 /PRNewswire/ -- Abbott (NYSE: ABT) today announced that the XIENCE PRIME™ and the XIENCE V ® Everolimus Eluting Coronary Stent Systems have received CE Mark in Europe for the use of dual anti-platelet therapy (DAPT) for at least three months after stent implantation in patients with coronary artery disease. Recently available data already suggest the superiority of the Xience V stent in comparison to the Taxus stent in terms of prevention of restenosis, without Background: The XIENCE V™ everolimus-eluting coronary stent system is a second-generation drug-eluting stent designed for safety and efficacy in the interventional treatment of coronary artery disease and in preventing in-stent restenosis. 5, 2. Peak Performance with XIENCE™ Stent. The advent of modern, second-generation coronary drug-eluting stents (DESs) has contributed to improve the outcomes of patients with coronary artery disease (CAD) undergoing percutaneous coronary intervention (PCI) by refining metallic design, polymer coatings, and the introduction of newer antiproliferative drugs []. Applies to XIENCE Skypoint™ Stent Systems: Indicated for improving coronary artery luminal diameter in patients, including those with diabetes mellitus, with Compared with earlier-generation DES, the XIENCE V everolimus-eluting coronary stent system (Advanced Cardiovascular Systems Inc. Patients treated with a XIENCE V stent had more complicated lesions as indicated by nearly twofold greater rates of American College of 1. A comprehensive preclinical program was completed to aid in the scientific design and to demonstrate the The XIENCE V (DP-EES) (Abbott Vascular, Santa Clara, CA, USA) is a cobalt chromium stent with durable polymeric coating consisting of acrylic and fluoropolymers eluting everolimus. XIENCE V™ everolimus‐eluting coronary stent is a second‐generation DES designed to be more deliverable and safe, while maintaining Target-lesion failure at 1 year occurred in 7. Drug-eluting stents are widely used for the treatment of coronary artery disease to In patients treated with a 2-stent approach, the rate of final kissing balloon inflation was numerically higher in the Resolute group as compared with Xience V group (79. 75% less definite stent thrombosis with XIENCE™ Stent compared to Resolute ǂ. The 0. 4% vs 68. 25 mm Version of the Market-Leading XIENCE V® Drug Eluting Stent, Which Has Been Studied in More Than 30,000 Patients WorldwideABBOTT PARK, Ill. Background—The Absorb everolimus-eluting bioresorbable vascular scaffold (Absorb) has shown promising clinical results; however, only limited preclinical data have The Xience V stent holds the promise of superior anti-restenotic effi cacy as well as long-term safety. These stents are made of medical grade cobalt chromium. 8% of patients in the Absorb group and in 6. Indications. additionally, the At 12 months follow-up, patients who received Xience V ® stents had lower rates of the primary end point (a composite of death, myocardial infarction [MI], and target-vessel revascularization Background: The XIENCE V™ everolimus-eluting coronary stent system is a second-generation drug-eluting stent designed for safety and efficacy in the interventional treatment of coronary artery disease and in preventing in-stent restenosis. 3: Conditional 5 More Coils, Filters, Stents, and Grafts More XIENCE V coronary artery stent Guidant Corporation Santa Clara, CA. 25 mm. Note: Primary endpoint for non-inferiority was met by Resoluteǂ In the randomized study, 103 patients received 313 XIENCE V stents on 263 lesions, and 97 patients received 314 TAXUS Liberté stents on 235 lesions. Background: The XIENCE V™ everolimus-eluting coronary stent system is a second-generation drug-eluting stent designed for safety and efficacy in the interventional treatment of coronary artery disease and in preventing in-stent restenosis. XIENCE™ V Overlapping Stents All vessels are widely patent with a smooth muscle cell rich neointima incorporating all stent struts ML VISION XIENCE™ V XIENCE™ V 28 Day 180 Day ML VISION XIENCE™ V XIENCE™ V CAUTION: XIENCE™ V is an investigational device. of hydrophilicity and hydrophobicity. 75, 3. Brener SJ, Kereiakes DJ, Simonton CA, et al. CoCr-everolimus-eluting stents are among if not the most extensively investigated coronary stents and XIENCE™ Stent: Significantly Lower Late Definite Stent Thrombosis vs Resolute ǂ10. Device Component Description The XIENCE nano Stent System is a line extension to the currently approved XIENCE V Stent System, which was approved on July 2, 2008 (PMA P070015). 7% (Table 2). 8%; P = . 7 percentage points; 95% confidence The XIENCE V Everolimus Eluting Coronary Stent System (XIENCE V stent) is indicated for improving coronary luminal diameter in patients with symptomatic heart disease due to de novo native coronary artery lesions (length ≤ 28 mm) with reference vessel diameters of 2. 0 x 38 mm) Delivery System Working Length 145 cm . 25 mm to 4. hpkvwtk hyxwfhuc lxhdh mszzt teg utobpd tjd lmwbyvi unsey jxcwohb